Pharmaxis battered by negative CHMP trend vote for cystic fibrosis drug
This article was originally published in Scrip
Executive Summary
Pharmaxis has been hit hard by the news that it is unlikely to receive a positive EU opinion for its cystic fibrosis therapy Bronchitol (inhaled mannitol) in the wake of a negative trend vote from the CHMP.